This is because FPN is the only HAMP target known to date and is inhibited by HAMP at the posttranslational level.4,5 To safeguard against any confounding effects secondary to overt AAA pathology, we focused on the earlier time point of 2 days of AngII infusion. Here, HAMP is linked to triple-A syndrome.